The inhibition of blood platelet aggregation and secretion was studied using covalent thiolreagents,
malei
mides, or
mercuribenzoates, or using inhibitors of protein disulfide iso
merase (PDI),bacitracin or antibodies to PDI. As expected, both types of inhibitors were effective against sti
mulationby nor
mal physiologic sti
muli. On the other hand, when sti
mulation was initiated with the peptideLSARLAF, that specifically activates the integrin
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>IIb
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">3 (the fibrinogen receptor), the PDI inhibitorswere without effect. LSARLAF-induced aggregation was, however, inhibited by the sulfhydryl reagents.To further investigate the role of sulfhydryl-containing proteins and
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>IIb
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">3, platelets were labeled with
me
mbrane-i
mper
meant sulfhydryl reagents. Nine bands were found labeled on gel electrophoresis. Twoof the labeled bands were identified as
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>IIb and
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">3. The conclusions are that while PDI is required forplatelet aggregation and secretion, an additional sulfhydryl-dependent step or protein is also required.This latter reaction occurs at the level of
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>IIb
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">3. In distinction to
most literature reports, at least asubpopulation of
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>IIb
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">3 contains free sulfhydryl groups, consistent with the possibility that it is a substratefor PDI or part of the sulfhydryl-dependent response.